These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16425898)

  • 21. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic therapy of psoriatic arthritis.
    Gladman DD
    Reumatismo; 2007; 59 Suppl 1():85-7. PubMed ID: 17828353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
    So A; Inman RD
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Etanercept].
    Sparsa A
    Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):861-76. PubMed ID: 16327716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapidly progressive destructive arthritis in psoriatic arthritis sine psoriasis: do bone resorption marker levels predict outcome of bone destruction in psoriatic arthritis?
    Taniguchi Y; Kumon Y; Shimamura Y; Kobayashi S; Terada Y
    Mod Rheumatol; 2011 Feb; 21(1):106-8. PubMed ID: 20625790
    [No Abstract]   [Full Text] [Related]  

  • 26. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
    Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
    Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?
    Więsik-Szewczyk E; Kucharczyk A; Świerkocka K; Rutkowska E; Jahnz-Różyk K
    Clin Rheumatol; 2017 Jul; 36(7):1677-1681. PubMed ID: 28488125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drugs for rheumatoid arthritis.
    Med Lett Drugs Ther; 2021 Nov; 63(1637):177-184. PubMed ID: 35085210
    [No Abstract]   [Full Text] [Related]  

  • 32. Etanercept in the treatment of psoriatic arthritis.
    Puig L; López-Ferrer A; Laiz A
    Actas Dermosifiliogr; 2015 May; 106(4):252-9. PubMed ID: 25455504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.
    Wong VK; Lebwohl MG
    Expert Opin Biol Ther; 2005 Nov; 5(11):1505-13. PubMed ID: 16255653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review.
    Acosta Felquer ML; Coates LC; Soriano ER; Ranza R; Espinoza LR; Helliwell PS; FitzGerald O; McHugh N; Roussou E; Mease PJ
    J Rheumatol; 2014 Nov; 41(11):2277-85. PubMed ID: 25362711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and management of psoriatic arthritis.
    Balakrishnan C; Madnani N
    Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S18-24. PubMed ID: 23974691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and management of psoriatic arthritis.
    Brockbank J; Gladman D
    Drugs; 2002; 62(17):2447-57. PubMed ID: 12421102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs.
    Marchesoni A; Lubrano E; Cauli A; Ricci M; Manara M
    J Rheumatol Suppl; 2015 Nov; 93():61-4. PubMed ID: 26523060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
    Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
    Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Joint count reliability in psoriatic arthritis observational trials--an unreported problem.
    Tillett W; Shaddick G; Korendowych E; de Vries CS; McHugh N
    Rheumatology (Oxford); 2012 Jul; 51(7):1333-4. PubMed ID: 22562935
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.